IBOGF - Universal Ibogaine appoints Nick Karos to the Board of Directors
(TheNewswire)
Calgary, AB – TheNewswire - September 6, 2022 – Universal Ibogaine Inc.( TSXV:IBO ) ( OTC:IBOGF ) (“ UI ” or the“ Company ”), a life sciences company with a mission to delivermedicalized ibogaine-centered addiction care, advises that it hasappointed Nicholas (“Nick”) Karos, CEO of the Company, to itsBoard of Directors of UI effective September 6, 2022. UI will holdits Annual Meeting of Shareholders in Vancouver on October 3, 2022,and at that time the existing group of 5 Directors, including Mr.Karos, will stand for election to the Board.
Nick’s primary focus as CEO is completing thenecessary financing to enable UI to advance towards ibogaine basedclinical trials as the next phase in its key strategic priorities withHealth Canada.
About UniversalIbogaine Inc.
UI is a life sciences company, with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder, andultimately to utilize that protocol globally through planned futurelicensing agreements. UI is concurrently developing a state of the art holisticaddiction treatment protocol at its Kelburn Recovery Centre that,which when paired with the planned ibogaine detox protocol, isintended to revolutionize the way we treat addiction and drasticallyimprove the lives of individuals and families affected byaddiction.
NEITHER THE TSXVENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM ISDEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTSRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.
CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS
?This news release may containforward-looking statements and information. Forward-lookinginformation is frequently characterized by words such ?as"plans", "expect", "project","intend", "will", "believe","anticipate", "estimate", "scheduled",??"potential", or other similar words, or statementsthat certain events or conditions "may", "should"or ??"could" occur. The forward-looking statements andinformation are based on certain key expectations ?and assumptionsmade by UI. Although UI believes that the expectations andassumptions on which the forward-?looking statements are based arereasonable, undue reliance should not be placed on theforward-?looking statements because UI can give no assurance thatthey will prove to be correct.
Since ?forward-looking statementsaddress future events and conditions, by their very nature theyinvolve ?inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated ?due to a numberof factors and risks, which include, but are not limited to, risksthat required ?regulatory approvals are not obtained. The reader iscautioned that assumptions used in the ?preparation of suchinformation, although considered reasonable by UI at the time of?preparation, may prove to be incorrect and readers are cautionednot to place undue reliance on ?forward-looking information, whichspeaks only to conditions as of the date hereof. UI does not?undertake any obligation to release publicly any revisions toforward-looking information contained ?herein to reflect events orcircumstances that occur after the date hereof or to reflect theoccurrence ?of unanticipated events, except as may be required underapplicable securities laws. ?
For furtherinformation:
InvestorRelations: Dugan Selkirk,IR Manager
dugan.selkirk@universalibogaine.com
Related Links
Copyright (c) 2022 TheNewswire - All rights reserved.